ELIAS Animal Health

ELIAS Animal Health is a medical biotechnology company focused on advancing novel targeted T cell-based immunotherapies for the treatment of canine cancers. Their flagship product, the ELIAS Cancer Immunotherapy (ECI), is an adoptive cell therapy designed to treat osteosarcoma, a deadly form of bone cancer in dogs.

ECI is a first-in-class personalized immunotherapy that works by conditioning the immune system to recognize a patient's unique cancer. A vaccine is created from the dog's own cancer cells, priming their immune cells to identify the cancer. These primed immune cells are then collected through apheresis, activated, and reinfused into the patient, where they travel throughout the body to attack the cancer cells.

In January 2024, the USDA determined that data from ELIAS's pivotal ECI-OSA-04 study demonstrated a reasonable expectation of efficacy for treating canine osteosarcoma, a critical milestone toward licensure. This two-arm field study, involving 100 dogs, is one of the largest clinical trials conducted in canine cancer.

ELIAS has demonstrated the cancer-killing capabilities of ECI through in vitro studies and clinical trials. Results from a previous trial found several long-term survivors among dogs with appendicular osteosarcoma treated with ECI. Another trial completed enrollment in early 2022 with over 100 dogs across 10 US sites.

Prior to commercial launch expected in late 2024, ECI remains available as an experimental biologic under ELIAS's existing nine CFR 103.3 authorization. The company is pursuing a USD 10 million Series A to support manufacturing expansion, commercial launch, and pipeline development, including novel therapies like oncolytic immunotherapy and combination studies with checkpoint inhibitors.